| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRNA | Ordinary Shares | Award | $0 | +200K | +1.5% | $0.00 | 13.5M | 01 Feb 2025 | Direct | F1, F2 |
| transaction | VRNA | Ordinary Shares | Tax liability | -$1.2M | -167K | -1.24% | $7.16 | 13.3M | 03 Feb 2025 | Direct | F1, F3, F4, F5 |
| Id | Content |
|---|---|
| F1 | Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| F2 | Represents an award of Ordinary Shares upon vesting of Performance Restricted Share Units in connection with the Issuer's first commercial sale of ensifentrine. |
| F3 | Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units and the Performance Restricted Share Units. |
| F4 | The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on January 31, 2025 divided by eight (8). |
| F5 | Consists of (i) 2,725,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 340,625 ADSs); and (ii) 10,601,848 Ordinary Shares underlying 1,325,231 ADSs. |